AMENDMENT NO. 1 TO INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • October 11th, 2022 • Arcus Biosciences, Inc. • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) to the Investor Rights Agreement dated May 27, 2020 (“Agreement”), is entered into as of October 11, 2022 (the “Amendment Execution Date”), by and between Arcus Biosciences, Inc. (“Arcus”) and Gilead Sciences, Inc. (“Gilead”). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement to the extent defined therein.
